RTW Investments purchased 16,010,524 shares of Erasca for approximately $189.23 million in Q1 2026, with the position's value rising to $261.42 million by quarter-end. The clinical-stage biotech company, which develops oral inhibitors targeting the RAS/MAPK pathway for cancer treatment, has seen its stock surge 800% over the past year. The investment reflects confidence in Erasca's lead program ERAS-0015, which showed encouraging early data in KRAS-driven cancers, and the company's strong cash position of $408.5 million expected to fund operations into late 2028.

Law firm Bragar Eagel & Squire is investigating Erasca, Inc. following a patent infringement allegation from Revolution Medicines regarding the company's ERAS-0015 drug candidate. The disclosure triggered a significant stock price decline of approximately 48%, dropping from $19.15 to $9.90 per share on April 28, 2026. The firm is seeking stockholders who suffered losses to discuss potential legal claims.

Law firm Bragar Eagel & Squire is investigating Erasca, Inc. following a patent infringement allegation from Revolution Medicines regarding the company's ERAS-0015 drug candidate. The disclosure triggered a significant stock price decline of approximately 48%, dropping from $19.15 to $9.90 per share on April 28, 2026. The firm is seeking stockholders who suffered losses to discuss potential legal claims.

Siren hedge fund purchased 2.49 million shares of Erasca (ERAS) worth $29.39 million in Q1 2026, bringing its total position to 11.2 million shares valued at $181.93 million. The investment comes as Erasca's stock has surged 700% over one year following encouraging early clinical data for its ERAS-0015 cancer therapy targeting RAS-driven tumors. The company is well-funded with $409 million in cash through mid-2028.

Erasca announced a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015, a pan-RAS molecular glue, in combination with Merck's pembrolizumab (KEYTRUDA®) for treating RAS-mutant solid tumors. The AURORAS-1 Phase 1 trial showed favorable safety, tolerability, and clinical responses at low doses. Merck will supply pembrolizumab at no cost to support the proof-of-concept study.

The Schall Law Firm is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations following the company's disclosure on April 28, 2026, that it received a patent infringement letter from Revolution Medicines regarding its ERAS-0015 drug candidate, along with trade secret misappropriation allegations. The announcement triggered a 48.3% stock price decline on the same day.

Erasca (ERAS) stock declined 7.33% on Monday following news that Merck ended acquisition discussions with competitor Revolution Medicines over valuation disagreements. The deal would have valued Revolution Medicines at approximately $30 billion. Both companies develop RAS-pathway cancer therapies, and the failed deal sparked investor concerns about the sector's valuation environment.

Erasca Inc (NASDAQ: ERAS), a clinical-stage precision oncology company, announced the successful closing of its upsized public offering of 25.875 million shares at $10.00 per share, generating approximately $258.8 million in gross proceeds. The company plans to use the net proceeds to fund research and development of its RAS/MAPK pathway-driven cancer therapies and for general corporate purposes.

Erasca, Inc., a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an upsized public offering of 22.5 million shares at $10.00 per share, generating $225 million in gross proceeds. The offering is expected to close on January 23, 2026, with proceeds to be used for R&D of product candidates and general corporate purposes.

The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.

Clinical-stage biotech Erasca reported Q2 2025 results, highlighting reduced operating expenses and progress in two RAS-pathway cancer therapy clinical trials entering Phase 1, while maintaining a strong cash position to fund operations through 2028.

Erasca, a clinical-stage precision oncology company, announced the advancement of its RAS-targeting franchise, with IND clearance for ERAS-0015 and IND submission for ERAS-4001, both ahead of schedule. The company expects to report Phase 1 monotherapy data for both programs in 2026 and has a projected cash runway of more than 3 years.